Deep-pocketed investors have adopted a bearish approach towards Pfizer PFE, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PFE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 14 extraordinary options activities for Pfizer. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 7% leaning bullish and 71% bearish. Among these notable options, 3 are puts, totaling $132,651, and 11 are calls, amounting to $851,053.
Projected Price Targets
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $40.0 for Pfizer during the past quarter.
Analyzing Volume & Open Interest
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Pfizer's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Pfizer's significant trades, within a strike price range of $20.0 to $40.0, over the past month.
Pfizer Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | CALL | TRADE | BEARISH | 07/05/24 | $9.5 | $9.45 | $9.45 | $20.00 | $188.9K | 204 | 400 |
| PFE | CALL | TRADE | BEARISH | 07/05/24 | $9.5 | $9.45 | $9.45 | $20.00 | $188.9K | 204 | 0 |
| PFE | CALL | SWEEP | BEARISH | 06/18/26 | $3.85 | $3.6 | $3.6 | $30.00 | $107.6K | 10.1K | 355 |
| PFE | CALL | SWEEP | BEARISH | 10/18/24 | $3.25 | $3.2 | $3.2 | $27.00 | $95.3K | 867 | 299 |
| PFE | CALL | TRADE | NEUTRAL | 01/16/26 | $6.7 | $5.4 | $6.15 | $25.00 | $62.1K | 17.2K | 0 |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.
Pfizer's Current Market Status
- Trading volume stands at 16,059,296, with PFE's price down by -2.27%, positioned at $28.88.
- RSI indicators show the stock to be may be approaching overbought.
- Earnings announcement expected in 54 days.
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with Benzinga Pro for real-time alerts.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
